Societal Costs and Outcomes of Medical and Recreational Marijuana Policies in the United States: A Systematic Review

Med Care Res Rev. 2022 Dec;79(6):743-771. doi: 10.1177/10775587211067315. Epub 2022 Jan 22.

Abstract

Significant support exists in the United States for legalization of marijuana/cannabis. As of 2021, 36 states and four territories approved the legalization of medical cannabis via medical marijuana laws (MMLs), and 15 states and District of Columbia (DC) have adopted recreational marijuana laws (RMLs). We performed structured and systematic searches of articles published from 2010 through September 2021. We assess the literature pertaining to adolescent marijuana use; opioid use and opioid-related outcomes; alcohol use; tobacco use; illicit and other drug use; marijuana growing and cultivation; employment, earnings, and other workplace outcomes; academic achievement and performance; criminal activity; perceived harmfulness; traffic and road safety; and suicide and sexual activity. Overall, 113 articles satisfied our inclusion criteria. Except for opioids, studies on use of other substances (illicit drugs, tobacco, and alcohol) were inconclusive. MMLs and RMLs do not generate negative outcomes in the labor market, lead to greater criminal activity, or reduce traffic and road safety.

Keywords: costs; laws; marijuana; medical; outcomes; policies; recreational.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Adolescent
  • Analgesics, Opioid
  • Cannabis*
  • Humans
  • Illicit Drugs*
  • Medical Marijuana* / therapeutic use
  • Policy
  • United States

Substances

  • Medical Marijuana
  • Analgesics, Opioid
  • Illicit Drugs